register

News & Trends - Pharmaceuticals

Viatris CEO on post-merger roadmap

Health Industry Hub | January 18, 2021 |

Pharma News: Following Mylan and Pfizer’s Upjohn established medicine business merger to become Viatris, CEO Michael Goettler presented a growth roadmap, including workforce reduction, for the new company at the recent J.P. Morgan Healthcare Conference.

Michael Goettler praised Viatris’ commercial presence, manufacturing strength and global supply network, as well as its medical, regulatory and development capabilities, which are now offered to potential partners as a platform.

Viatris’ short-term plan covering the next four years is focused on stabilising the business and investing in its own pipeline.

That means minimising costs – an effort that will involve reducing 20% of the combined businesses’ 45,000 workforce. The aim is to save $1 billion annually by laying off workers and closing, downsizing or selling up to 15 manufacturing facilities.

Viatris top-selling pain drug Lyrica is facing early generic competition in Japan despite an ongoing patent dispute. China’s growing volume-based procurement (VBP) scheme, which is designed to further lower the price of off-patent drugs, is also hitting the Upjohn business hard.

China is a key growth opportunity for Viatris over the long term, but it’s still only 10% of its business right now, Michael Goettler pointed out, adding that it can absorb the initial VBP-caused decline. Part of that will come from introducing legacy Mylan’s portfolio to the Chinese market.

“We have adapted very quickly and very well to the volume-based procurement impact, we … rightsized hospital business but invested in the retail space,” Michael Goettler said.

The retail space which is shielded from VBP and is more self-pay now represents more than one-third of Viatris’ China business and is growing at over 20%.

Goettler painted Viatris as a partner of choice in China. “We have an absolute premium infrastructure in China that can promote in multiple channels – hospital, retail and digital,” he said.

M&A is potentially the way forward for Viatris to achieve further growth. The company has a natural erosion phase that needs to be compensated by not just internal R&D but deal-making. A lot of that will come in the second phase of the post-merger plans in which the company will have more financial flexibility to strike business deals.


News & Trends - MedTech & Diagnostics

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Health Industry Hub | April 17, 2025 |

Hospitals shouldn’t be forced to grovel to private health insurers to secure funding for essential, lifesaving medical devices. But thanks […]

More


News & Trends - Pharmaceuticals

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Health Industry Hub | April 17, 2025 |

Lung cancer is Australia’s leading cause of cancer deaths. Local experts are set to lead a new frontier in personalised […]

More


Medical and Science

The high cost of record low research funding

The high cost of record low research funding

Health Industry Hub | April 17, 2025 |

Australia has delivered some of the world’s most transformative health and medical breakthroughs – the cochlear implant, the HPV vaccine, […]

More


News & Trends - Pharmaceuticals

UCB secures dermatology indication with first dual IL-17A/F inhibitor

UCB secures dermatology indication with first dual IL-17A/F inhibitor

Health Industry Hub | April 17, 2025 |

UCB’s IL-17A and IL-17F inhibitor has been added to the Australian Register of Therapeutic Goods (ARTG) for adults with moderate […]

More


This content is copyright protected. Please subscribe to gain access.